Anti-Phospholipase A2 Receptor Antibody Trajectories for Predicting Prognosis in Patients with Phospholipase A2 Receptor-Associated Membranous Nephropathy
Serum anti-PLA2R antibody trajectories represent a robust prognosis biomarker in MN, useful for risk stratification and clinical decision-making. Patients with high-stable or rising antibody trajectories require heightened clinical attention due to significantly increased risks of renal function decline, clinical non-remission, and relapse.
Authors
- Aijuan LI (ORCID: https://orcid.org/0000-0003-1685-1945)
- Dacheng Chen (ORCID: https://orcid.org/0000-0002-6007-164X)
- Siwen Gong
- Zhihong Liu
- Zhe Li
- Mengyao Zeng
- Feng Xu
Institutions
- National Clinical Research (US)
- Southern Medical University (CN)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1159/000550352
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00